Collegium settles patent dispute with Teva

Massachusetts-based Collegium Pharmaceutical has reached a settlement agreement with Teva, resolving its patent litigation over pain medication.

The settlement, which was announced today, September 30, resolves the patent litigation Collegium brought in response to Israeli drug manufacturer Teva’s plans to market a generic version of Xtampza ER (oxycodone).

Under the agreement, Collegium will grant Teva a licence to market its generic version in the US beginning on or after September 2, 2033 (subject to US Food and Drug Administration approval).

Collegium has 19 Orange Book-listed patents covering Xtampza ER, with expiries through to 2036.

Teva has agreed to a consent judgment confirming that its proposed generic products infringe Collegium’s asserted patents. It has also agreed that Collegium’s patents are valid and enforceable with respect to the proposed generic products.

Shirley Kuhlmann, executive vice president and general counsel of Collegium, said: “As a company committed to being the leader in responsible pain management, we seek to deliver scientific innovation through differentiated products for people suffering from pain.

“We are pleased with the outcome of the Abbreviated New Drug Application settlement with Teva because it highlights the value of that innovation in the context of the Xtampza ER franchise.”

Last month, the US Department of Justice charged Teva with conspiring to fix prices, rig bids, and allocate customers for generic drugs. Find out more here.

Did you enjoy reading this story?  Sign up to our free daily newsletters and get stories sent like this straight to your inbox.